Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

July 31, 2010

Study Completion Date

June 30, 2011

Conditions
Cytomegalovirus Infections
Interventions
BIOLOGICAL

CMV CTL infusion

Three dose levels will be explored. The lowest dose level will be 1x10\^7cells/m2 and the highest will be 1x10\^8/m2. 3-6 pts will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval. Additional patients will be treated at dose level 1 in order to assess the secondary objective of virus-specific immunity from the CTL infusions

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Baylor College of Medicine

OTHER

NCT00078533 - Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant | Biotech Hunter | Biotech Hunter